EUVIMEDEUVIMED entdecken
Crossref

Clinical Observation of Probucol for Nonproliferative Diabetic Retinopathy

苏平 蒋

Hans Journal of Ophthalmology · 2014

DOI: 10.12677/hjo.2014.32003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hans Journal of Ophthalmology, 2014. Verfasst von 苏平 蒋. Die Arbeit nennt 15 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

目的:观察丙丁酚治疗非增殖性糖尿病视网膜病变(NPDR)的临床疗效。方法:于2012年1月至2013年8月选取非增殖性糖尿病视网膜病变患者68例作为研究对象,再将非增殖性糖尿病视网膜病变(NPDR)患者分为四组:即:A组、强化治疗+丙丁酚组,共17例;B组、强化治疗组,共17例;C组、常规治疗 + 丙丁酚组,共17例;D组、常规治疗组,共17例,避免服用其它抗氧化剂。A、C组DR患者予丙丁酚0.375 g,每日2次。平均随访11.58 ± 0.17个月。并比较观察4组干预前、1年后的视力、眼底及血脂(TC、LDLC)变化。结果:最终随访发现:1、A、C组NPDR患者的眼底情况较干预前显著改善(P 0.05);B、D组患者的眼底情况均无显著改善(P > 0.05)。2、A、C组患者最佳矫正视力均较干预前显著提高(P 0.05);B、D组患者最佳矫正视力均无显著提高(P > 0.05)。3、A、C组患者TC、LDLC水平均显著低于干预前(P 0.05);且干预后A、C组间TC、LDLC水平无显著性差异(P > 0.05)。结论 丙丁酚治疗非增殖性糖尿病视网膜病变疗效显著,且并发症较少。 Objective: To observe the clinical efficacy of probucol for nonproliferative diabetic retinopathy (NPDR).

Methods

68 patients with nonproliferative diabetic retinopathy (NPDR) were studied from Jan. 2012 to Aug. 2013. These patients were divided into four groups. Group A consisted of 17 patients receiving enhanced therapy and probucol; Group B consisted of 17 patients receiving enhanced therapy; Group C consisted of 17 patients receiving regular therapy and probucol; Group D consisted of 17 patients receiving regular therapy. Group A and Group C were given probucol of 0.375 g twice per day. All patients were followed up for average 11.58 ± 0.17 months. The changes of best corrected visual acuity, fundus, total cholesterol (TC), low density lipoprotein- cholesterol (LDL-C) before therapy and one year after therapy were observed.

Results

1) The fundi of Group A and Group C were significantly improved (P 0.05); but the difference between the fundi of Group B and of Group D was not statistically significant (P > 0.05). 2) The best corrected visual acuity of Group A and Group C was improved significantly (P 0.05); but the best corrected visual acuity of Group B and Group D did not change significantly (P > 0.05). 3) The TC and LDLC level of Group A and Group C decreased significantly (P 0.05); There was no significant difference between the TC and LDLC level of Group A and of Group C (P > 0.05).

Conclusion

The efficacy of probucol for nonproliferative diabetic retinopathy is significant with less complications.

Zitieren

APA

蒋, 苏. (2014). Clinical Observation of Probucol for Nonproliferative Diabetic Retinopathy. Hans Journal of Ophthalmology. https://doi.org/10.12677/hjo.2014.32003

Vancouver

蒋 苏. Clinical Observation of Probucol for Nonproliferative Diabetic Retinopathy. Hans Journal of Ophthalmology. 2014. doi:10.12677/hjo.2014.32003

BibTeX
@article{2014,
  author = {蒋, 苏平},
  title = {Clinical Observation of Probucol for Nonproliferative Diabetic Retinopathy},
  journal = {Hans Journal of Ophthalmology},
  year = {2014},
  doi = {10.12677/hjo.2014.32003}
}
Kostenlos starten →